Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat
Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.
